×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [140]
湖南大学 [39]
山东大学 [17]
四川大学 [13]
暨南大学 [12]
江苏大学 [11]
更多...
内容类型
期刊论文 [355]
项目 [17]
会议论文 [5]
学位论文 [1]
发表日期
2018 [378]
学科主题
Analysis [2]
Chemistry [2]
Biochemist... [1]
Chemistry,... [1]
Health Car... [1]
Pharmacolo... [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共378条,第1-10条
帮助
限定条件
发表日期:2018
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent
期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 61, 期号: 23, 页码: 10412-10414
作者:
Wang, Yibing
;
Liu, Hong
收藏
  |  
浏览/下载:78/0
  |  
提交时间:2019/01/08
Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction
期刊论文
European journal of medicinal chemistry, 2018, 卷号: 163, 页码: 597-609
作者:
Chen, Danqi
;
Chen, Yuehong
;
Lian, Fulin
;
Chen, Liu
;
Li, Yanlian
收藏
  |  
浏览/下载:91/0
  |  
提交时间:2019/01/08
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma
期刊论文
European journal of medicinal chemistry, 2018, 卷号: 163, 页码: 671-689
作者:
Wang, Qi
;
Dai, Yang
;
Ji, Yinchun
;
Shi, Huanyu
;
Guo, Zuhao
收藏
  |  
浏览/下载:85/0
  |  
提交时间:2019/01/08
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia
期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 160, 页码: 61-81
作者:
Liu, Xuesong
;
Wang, Beilei
;
Chen, Cheng
;
Jiang, Zongru
;
Hu, Chen
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2019/01/11
ABL kinase
Kinase inhibitor
ABL mutant
CML
Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles
期刊论文
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 卷号: 26, 期号: 22, 页码: 5780-5791
作者:
Guo, Bin
;
Guo, Shimeng
;
Huang, Jing
;
Li, Jingya
;
Li, Jia
收藏
  |  
浏览/下载:43/0
  |  
提交时间:2019/01/08
GPR40 agonist
2,3-Dihydrobenzo[b][1,4]dioxine
Insulin secretion
Type 2 diabetes mellitus
Identification of a cellularly active SIRT6 allosteric activator
期刊论文
NATURE CHEMICAL BIOLOGY, 2018, 卷号: 14, 期号: 12, 页码: 1118-+
作者:
Huang, Zhimin
;
Zhao, Junxing
;
Deng, Wei
;
Chen, Yingyi
;
Shang, Jialin
收藏
  |  
浏览/下载:91/0
  |  
提交时间:2019/01/08
ETA as a novel Kv2.1 inhibitor ameliorates beta-cell dysfunction and hyperglycaemia
期刊论文
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2018, 卷号: 45, 期号: 12, 页码: 1257-1264
作者:
Zhou, Tingting
;
Du, Mengfan
;
Zhao, Tong
;
Quan, Lingling
;
Zhu, Zhiyuan
收藏
  |  
浏览/下载:94/0
  |  
提交时间:2019/01/08
beta cell
apoptosis
glucose-stimulated insulin secretion
T2DM
Adenine derivatives invert high glucose-induced thioredoxin-interacting protein overexpression
期刊论文
CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 卷号: 92, 期号: 6, 页码: 1998-2008
作者:
Zhong, Li
;
Liu, Qing
;
Ting, Yan Sie
;
Vun Yien Thien
;
Kalong, Nurwafa Syafiqah Binti
收藏
  |  
浏览/下载:89/0
  |  
提交时间:2019/01/08
adenine derivative
structural optimization
thioredoxin-binding protein-2
thioredoxin-interacting protein
vitamin D3-upregulated protein-1
Personalized Medicines Molecular Signature-Based Drug Discovery and Development, Strategic Priority Research Program of Chinese Academy of Sciences[XDA12040307]
项目
项目编号: XDA12040307, 资助机构: Personalized Medicines Molecular Signature-Based Drug Discovery and Development, Strategic Priority Research Program of Chinese Academy of Sciences, 2018-
-
收藏
  |  
浏览/下载:0/0
  |  
提交时间:2020/07/01
Personalized Medicines-Molecular Signature-based Drug Discovery and Development Strategic Priority Research Programof Chinese Academy of Sciences[XDA12020347]
项目
项目编号: XDA12020347, 资助机构: Personalized Medicines-Molecular Signature-based Drug Discovery and Development Strategic Priority Research Programof Chinese Academy of Sciences, 2018-
-
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2020/07/01
©版权所有 ©2017 CSpace - Powered by
CSpace